PHASE 2 OPEN-LABEL EXTENSION STUDY (OLE) OF PATISIRAN, AN INVESTIGATIONAL siRNA INVESTIGATIONAL AGENT FOR FAMILIAL AMYLOID POLYNEUROPATHY (FAP)

¹Unidade Clinica de Paramiloidose, Hospital de Santo Antonio, Porto, Portugal; ²Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden; ³Centro Hospitalar Lisboa Norte-Hospital de Santa Maria, Lisbon, Portugal; ⁴Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil; ⁵The University Hospital of Muenster, Muenster, Germany; ⁶Hospital Son Llatzer, Palma de Mallorca, Spain; ⁷Hospital Clinic, Barcelona, Spain; ⁸Centre de Reference des Maladies Naueromusculaires et de la SLA, Hopital de la Timone, Marseille, France; ⁹Amyloidosis Center, Boston University, Boston, MA, USA; ¹⁰Alnylam Pharmaceuticals, Cambridge, MA, USA; ¹¹Centre Paris-Sud, APHP, Hopital de Bicetre, INSERM U788, Service de Neurologie, and Centre de Reference des Neuropathies Amyloides Familiales, Le Kremlin-Bicetre, France.